Short Interest in Terumo Corp. (OTCMKTS:TRUMY) Decreases By 79.4%

Key Points

• Short interest in Terumo Corp. has decreased by 79.4% in September, falling from 140,300 shares to 28,900 shares, indicating a significant reduction in bearish sentiment.
• Despite this, Terumo's stock price is currently down 0.4%, trading at $16.46, with a market capitalization of $24.37 billion.
• The company reported quarterly earnings of $0.20 per share, surpassing analyst estimates of $0.17, although it fell slightly short on revenue with $1.76 billion compared to the forecasted $1.80 billion.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 28,900 shares, a decline of 79.4% from the September 15th total of 140,300 shares. Based on an average daily volume of 234,000 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 234,000 shares, the days-to-cover ratio is presently 0.1 days.

Terumo Stock Down 0.4%

Shares of OTCMKTS TRUMY opened at $16.46 on Friday. The firm has a market capitalization of $24.37 billion, a PE ratio of 28.88 and a beta of 0.79. The company has a current ratio of 2.64, a quick ratio of 1.53 and a debt-to-equity ratio of 0.07. Terumo has a 1 year low of $15.64 and a 1 year high of $21.22. The firm's 50-day moving average is $17.43 and its 200-day moving average is $17.92.

Terumo (OTCMKTS:TRUMY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.03. Terumo had a net margin of 12.09% and a return on equity of 9.19%. The business had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.80 billion.

About Terumo

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.